Research programme: influenza vaccine - Akela Pharma

Drug Profile

Research programme: influenza vaccine - Akela Pharma

Latest Information Update: 18 Mar 2013

Price : $50

At a glance

  • Originator Nventa Biopharmaceuticals Corporation
  • Developer Akela Pharma
  • Class
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Influenza virus infections

Most Recent Events

  • 18 Mar 2013 9147415 - Akela Pharma no longer operating, no indication development was even ongoing at the time they went bankrupt as they'd turned to focus on Formulation Technologies, which was more of a CRO
  • 14 Mar 2013 Discontinued - Preclinical for Influenza virus infections in USA (Parenteral)
  • 14 Mar 2013 Akela Pharma and its subsidiaries cease operations
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top